评估变种病原性预测工具,以建立胚胎基因检测的非洲包容性指南
Kangping Zhou1, Kazzem Gheybi1, Pamela X Y Soh1
1Ancestry and Health Genomics Laboratory, Charles Perkins Centre, School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Camperdown, Sydney, NSW, Australia.
Communications medicine
|May 6, 2025
概括
变异性致病性预测工具 (VPPTs) 对非洲遗传数据的敏感性较低. 这项研究确定了VPPTs,可以改善非洲人口的罕见病原性变异预测,解决基因测试中的数据偏差.
科学领域:
- 基因组学就是基因组学.
- 生物信息学是一种生物信息学.
- 人口遗传学 人口遗传学
背景情况:
- 遗传生殖基因测试对于非洲患者来说是有限的,因为缺乏与祖先相关的基因组数据.
- 欧洲偏见的变异数据库和预测指南阻碍了多种不同人群的精确遗传分析.
- 在非洲人群中,变异性病原性预测工具 (VPPTs) 的性能在很大程度上尚未评估.
研究的目的:
- 用南非和欧洲男性前列腺癌遗传数据评估54个VPPT的性能.
- 为了确定VPPTs,在不同的祖先,特别是在非洲人群的最佳表现.
- 选数以百万计的未知意义的变异对潜在的功能和致癌影响.
主要方法:
- 对来自南非和欧洲男性的145,291种已知的致病性或良性变体进行了54次VPPT的评估.
- 分析了VPPT性能指标,包括灵敏度,特异性和错误阳性/负率.
- 使用优先级VPPTs选了530万种未知意义的变异.
主要成果:
- 与欧洲数据 (0.71) 相比,非洲数据 (0.66) 的VPPT灵敏度较低.
- 几个VPPT (MetaSVM,CADD,Eigen-raw,BayesDel-noAF,phyloP100way-脊椎动物,MVP) 在祖先之间表现良好.
- 特定工具显示出偏向祖先的表现 (例如,非洲的MutationTaster,欧洲的REVEL),但选定的工作流程缩小了非洲数据的预测差距.
结论:
- VPPT敏感性通常有利于欧洲遗传数据,突出现有的偏见.
- 该研究为选择VPPT提供了关键的指导方针,以提高非洲疾病研究中的罕见病原性变异预测.
- 这些发现旨在通过解决数据限制来提高非洲患者的基因测试准确性和结果.
相关概念视频
Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


